《新股消息》現代中藥(01643.HK)每股定價1.18元 一手中籤率10%
現代中藥(01643.HK)公布招股結果,發售價定於1.18元,略低於招股範圍(介乎每股0.92至1.47元)中間價,公開發售錄超購29.66倍,經重新分配後,公開發售股數增至30%。每手3,000股,中籤率為10%。該股將於明日(15日)上市。獨家保薦人為東吳證券。
公司預計,所得款項淨額約為1.17億元,當中44%用作擴大產能;16.8%用於擴大華南及華東的分銷網絡;10.2%用於透過媒體營銷及推廣活動提升品牌知名度;19.9%用於加大研發力度、採購質量管理設備及擴大產品組合;3.4%用於升級IT系統;以及5.7%用於一般營運用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.